Open an account

Acumen Pharmaceuticals

ABOS · NASDAQ

$2.02+$0.245 (+13.84%)TodayMarket closed ·
Prev close $1.77

About ABOS

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages and develops medicines and diagnostics for Alzheimer's disease. The company is headquartered in Newton, Massachusetts and currently employs 60 full-time employees. The company went IPO on 2021-07-01. The firm is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The firm is focused on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), in its Phase II ALTITUDE-AD clinical trial following Phase I results in early AD patients (patients with mild cognitive impairment or mild dementia due to AD). Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (IgG2), monoclonal antibody (mAb) that selectively targets the anti-amyloid-beta oligomer, has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic mouse models for AD. The firm is developing sabirnetug for IV administration once every four weeks (Q4W) for the treatment of early AD, and it has developing sabirnetug for subcutaneous administration.

Employees
60
Headquarters
Newton, Massachusetts
Listed
Jul 1, 2021
Sector
Health Care
Industry
Biotechnology
Website
acumenpharm.com

ABOS key statistics

Market cap
145.72M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
578.17K
Volume
784.65K
Open price
$1.78
High today
$2.07
Low today
$1.76
52 Week high
$3.60
52 Week low
$1.51

Acumen Pharmaceuticals (ABOS) at a glance

Acumen Pharmaceuticals (ABOS) last traded at $2.02, with a market cap of 145.72M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.76 and $2.07. The current price is 14.2% above the day's low and 2.7% below its high.

Volume so far is 784.65K shares, above the average of 578.17K shares a day.

Over the past year Acumen Pharmaceuticals has ranged from $1.51 to $3.60, and now sits 24% of the way up that range.

Acumen Pharmaceuticals met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.45 per share against an estimate of -$0.3745.

The average analyst price target is $7.75, 284.7% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 7 analystsAvg $7.75
Low
$5.05
Now
$2.02
High
$10.50

ABOS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 22.1% on average.

  1. Q3 FY24: reported -$0.50 per share against an estimate of -$0.3723
  2. Q4 FY24: reported -$0.62 per share against an estimate of -$0.4896
  3. Q1 FY25: reported -$0.48 per share against an estimate of -$0.6766
  4. Q2 FY25: reported -$0.68 per share against an estimate of -$0.5488
  5. Q3 FY25: reported -$0.44 per share against an estimate of -$0.6157
  6. Q4 FY25: reported -$0.41 per share against an estimate of -$0.4622
  7. Q1 FY26: reported -$0.33 per share against an estimate of -$0.4108
  8. Q2 FY26: reported -$0.45 per share against an estimate of -$0.3745

ABOS news

  • Press releaseBusiness Wire

    JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • Market-Moving News for March 16th

  • Preview: Acumen Pharmaceuticals's Earnings

  • Press releaseGlobe Newswire

    Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights

  • A Preview Of Acumen Pharmaceuticals's Earnings

  • Press releaseGlobe Newswire

    Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights

  • Acumen Pharmaceuticals Earnings Preview

Similar companies

Companies in the same industry as Acumen Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.